SCHEMBL8442124

SCHEMBL8442124

CC(C)Cc1nc(-c2ccc3[nH]nc(-c4ccc(O)c(F)c4)c3c2)n[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 2/20 0.48
MAPK1 P28482 8/20 0.44
MAPK3 P27361 2/20 0.44
MAP2K4 P45985 6/20 0.42
MAPKAPK3 Q16644 5/20 0.42
MAPK6 Q16659 5/20 0.42
MAPKAPK2 P49137 4/20 0.42
FGFR1 P11362 2/20 0.38
MAPKAPK5 Q8IW41 2/20 0.38
FGFR2 P21802 1/20 0.37
DYRK1A Q13627 5/20 0.37
PLK4 O00444 2/20 0.36
CDC7 O00311 1/20 0.36
DCLK1 O15075 1/20 0.36
MAPK13 O15264 1/20 0.36
DAPK3 O43293 1/20 0.36
DYRK3 O43781 1/20 0.36
JAK2 O60674 1/20 0.36
ROCK2 O75116 1/20 0.36
PRKD3 O94806 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5378295 0.90 CSNK1D (0.51) CSNK1DMAPK1MAPK3MAP2K4MAPKAPK3
SCHEMBL5372338 0.88 CSNK1D (0.49) CSNK1DMAPK1MAP2K4MAPKAPK3MAPK6
SCHEMBL8442884 0.88 CSNK1D (0.44) CSNK1DMAPK1MAP2K4MAPKAPK3MAPK6
SCHEMBL5383966 0.86 CSNK1D (0.49) CSNK1DMAPK1MAP2K4MAPKAPK3MAPK6
SCHEMBL5372967 0.85 CSNK1D (0.64) CSNK1DMAPK1MAP2K4MAPKAPK3MAPK6
SCHEMBL5393207 0.85 CSNK1D (0.47) CSNK1DMAPK1MAP2K4MAPKAPK3MAPK6
SCHEMBL5383738 0.85 CSNK1D (0.48) CSNK1DMAPK1MAPK3MAP2K4MAPKAPK3
SCHEMBL5377949 0.84 CSNK1D (0.54) CSNK1DMAPK1MAP2K4MAPKAPK3MAPK6
SCHEMBL5387313 0.84 CSNK1D (0.52) CSNK1DMAP2K4DYRK1ANTRK1CLK2
SCHEMBL5378169 0.82 CSNK1D (0.44) CSNK1DMAPK1MAP2K4MAPKAPK3MAPK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2005-01-13 US disclosed
US-20040127536-A1 Methods for treating an inflammatory condition or inhibiting JNK SIGNAL PHARMACEUTICALS, LLC 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127536-A1 Methods for treating an inflammatory condition or inhibiting JNK MAPK1, MAP3K1, MAPKAPK2 CSNK1D 349/4885MAPK1 1/4885MAPK3 22/4885
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith GPR119, JAK3, IGF1R CSNK1D 410/4885MAPK1 52/4885MAPK3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.